Role of renin-angiotensin system in adipose tissue dysfunction

Hypertension Research

Volumn 32, Issue 6, 2009, Pages 425-427

  Iwai, Masaru ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; GLUCOSE; INSULIN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ADIPOSE TISSUE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; DIABETES MELLITUS; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TISSUE METABOLISM; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ADIPOSE TISSUE; ANGIOTENSIN II; ANIMALS; CELL DIFFERENTIATION; HUMANS; INSULIN RESISTANCE; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 68249147664     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.55     Document Type: Review

References (30)

1. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 2007; 369: 201-207.
2. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005; 23: S9-S17.
3. Shiuchi T, Iwai M, Li H-S, Wu L, Min L-J, Li J-M, Okumura M, Cui T-X, Horiuchi M. Angiotensin II type 1 receptor blocker, valsartan, enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43: 1003-1010.
4. Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20: 579-586.
5. Shao J, Iwashita N, Ikeda F, Ogihara T, Uchida T, Shimizu T, Uchino H, Hirose T, Kawamori R, Watada H. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. Biochem Biophys Res Commun 2006; 344 1224-1233.
6. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-κB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 2008; 294: E345-E351.
7. Henriksen EJ. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 293: R974-R980.
8. Kirwan JP, del Aguila LF. Insulin signalling, exercise and cellular integrity. Biochem Soc Trans 2003; 31: 1281-1285.
9. Goossens GH, McQuaid SE, Dennis AL, van Baak MA, Blaak EE, Frayn KN, Saris WH, Karpe F. Angiotensin II: A major regulator of subcutaneous adipose tissue blood flow in humans. J Physiol 2006; 571: 451-460.
10. Shao J, Iwashita N, Ikeda F, Ogihara T, Uchida T, Shimizu T, Uchino H, Hirose T, Kawamori R, Watada H. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. Biochem Biophys Res Commun 2006; 344 1224-1233.
11. Sharma AM, Staels B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92: 386-395.
12. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006; 14(Suppl 5): 242S-249S.
13. Massiéra F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15: 2727-2729.
14. Iwai M, Tomono Y, Inaba S, Kanno H, Senba I, Mogi M, Horiuchi M. AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice. Am J Hypertens 2009 (in press).
15. Schling P. Expression of angiotensin II receptors type 1 and type 2 in human preadipose cells during differentiation. Horm Metab Res 2002; 34: 709-715.
16. Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P, Quignard-Boulange A. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005; 54: 991-999.
17. Tomono Y, Iwai M, Inaba S, Mogi M, Horiuchi M. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 2008; 21: 206-212.
18. Cabassi A, Coghi P, Govoni P, Barouhiel E, Speroni E, Cavazzini S, Cantoni AM, Scandroglio R, Fiaccadori E. Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat. J Clin Endocrinol Metab 2005; 90 2888-2897.
19. Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, Egan GF, McKinley MJ, Rodger PD, Sinclair AJ, Wark JD, Weisinger HS, Jois M, Weisinger RS. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 2008; 105: 6531-6536.
20. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611.
21. Tsuchida A, Yamauchi T, Kadowaki T. Nuclear receptors as targets for drug development: Molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin. J Pharmacol Sci 2005; 97 164-170.
22. Matsushita K, Wu Y, Okamoto Y, Pratt RE, Dzau VJ. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 2006; 48: 1095-1102.
23. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Higashiura K, Shimamoto K. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22: 1977-1982.
24. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocrine Reviews 2005; 26: 439-451.
25. Yvan-Charvet L, Even P, Lamandé N, Ferré P, Quignard-Boulangé A. Prevention of adipose tissue depletion during food deprivation in angiotensin type 2 receptor-deficient mice. Endocrinology 2006; 147: 5078-5086.
26. Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: Can we do better? Clin Ther 2007; 29: 1803-1824.
27. Kintscher U, Foryst-Ludwig A, Unger T. Inhibiting angiotensin type 1 receptors as a target for diabetes. Expert Opin Ther Targets 2008; 12: 1257-1263.
28. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047-1052.
29. Daugherty A, Cassis L. Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 2004; 14: 117-120.
30. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschöpe C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlöf B, Kintscher U, Unger T, Steckelings UM. Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008; 118: 2523-2532.